Arthur M. Krieg
Keine laufenden Positionen mehr
Profil
Arthur M.
Krieg is the founder of Coley Pharmaceutical Group, Inc. (founded in 1997), Translate Bio, Inc. (founded in 2011), and Checkmate Pharmaceuticals, Inc. (founded in 2015).
At Coley Pharmaceutical Group, Inc., he held the title of Chief Scientific Officer & Senior Vice President from 1997 to 2011.
At Translate Bio, Inc., he held the title of Chief Executive Officer from 2011 to 2013.
At Checkmate Pharmaceuticals, Inc., he held the titles of CEO, Director & Chief Scientific Officer from 2015 to 2018.
Dr. Krieg's former jobs included Chief Executive Officer at Translate Bio, Inc. from 2011 to 2014, Director at Cytos Biotechnology AG from 2012 to 2014, Chief Scientific Officer & Senior Vice President at Sarepta Therapeutics, Inc. in 2014, Professor at the University of Iowa, and Chief Scientific Officer at Oligonucleotide Therapeutics Society, Inc. from 2008 to 2011.
Dr. Krieg's education includes a doctorate from the University of Washington and an undergraduate degree from Haverford College.
Ehemalige bekannte Positionen von Arthur M. Krieg
Unternehmen | Position | Ende |
---|---|---|
CHECKMATE PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 12.12.2018 |
SAREPTA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 22.07.2014 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Direktor/Vorstandsmitglied | 31.05.2014 |
TRANSLATE BIO, INC. | Vorstandsvorsitzender | 01.01.2014 |
TRANSLATE BIO, INC. | Vorstandsvorsitzender | 01.01.2013 |
Ausbildung von Arthur M. Krieg
Haverford College | Undergraduate Degree |
University of Washington | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SAREPTA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Health Technology |
National Institute of Arthritis | Government |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Translate Bio, Inc.
Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |